Old Web
English
Sign In
Acemap
>
authorDetail
>
Ulrike Dernedde
Ulrike Dernedde
Medicine
Pathology
Afatinib
Chemotherapy
Internal medicine
4
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Evaluating the delay prior to primary care presentation in lung cancer patients
2020
Jalpa Kotecha
Allan Clark
Matthew Burton
Wei Yee Chan
Di Menzies
Ulrike Dernedde
Rachel Banham
Andrew M. Wilson
William Craig Martin
Show All
Source
Cite
Save
Citations (0)
P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial)
2017
Journal of Thoracic Oncology
Sanjay Popat
Laura Hughes
Mary OBrien
T. Ahmad
Conrad R. Lewanski
Ulrike Dernedde
Petra Jankowska
Clive Mulatero
R. Shah
J. Hicks
Tom Geldart
Mathilda Cominos
Gill Gray
James Spicer
Karen Bell
Yenting Ngai
Allan Hackshaw
Show All
Source
Cite
Save
Citations (0)
Poster SessionP3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial): Topic: EGFR Clinical
2017
Journal of Thoracic Oncology
Sanjay Popat
Laura Hughes
Mary OBrien
T. Ahmad
Conrad R. Lewanski
Ulrike Dernedde
Petra Jankowska
Clive Mulatero
R. Shah
J. Hicks
Tom Geldart
Mathilda Cominos
Gill Gray
James Spicer
Karen Bell
Yenting Ngai
Allan Hackshaw
Show All
Source
Cite
Save
Citations (0)
P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial): Topic: EGFR Clinical
2017
Journal of Thoracic Oncology
Sanjay Popat
L. Hughes
Mary O'Brien
T. Ahmad
Conrad Lewanski
Ulrike Dernedde
Petra Jankowska
Clive Mulatero
R. Shah
J. Hicks
Tom Geldart
Mathilda Cominos
Gill Gray
James Spicer
Karen Bell
Yenting Ngai
Allan Hackshaw
Show All
Source
Cite
Save
Citations (1)
1